Fast Market Research announces the availability of the new Global Markets Direct report, "Rheumatoid Arthritis - Pipeline Review, H2 2015", on their comprehensive research portal

Boston, MA -- (SBWire) -- 02/15/2016 --Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H2 2015', provides an overview of the Rheumatoid Arthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects.

Get More Details on this Report and a Full Table of Contents at Rheumatoid Arthritis - Pipeline Review, H2 2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

-The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Rheumatoid Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products

Reasons to Get this Report

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: 3SBio Inc., 4D Pharma Plc, 4SC AG, AB Science SA, AB2 Bio Ltd., AbbVie Inc., Ablynx NV, ACEA Biosciences, Inc., Addex Therapeutics Ltd, Advinus Therapeutics Ltd., Aegera Therapeutics Inc., Alder Biopharmaceuticals Inc., AlphaMab Co., Ltd, Amgen Inc., Amura Holdings Limited, Aprogen, Inc., Arena Pharmaceuticals, Inc., arGentis Pharmaceuticals, LLC, Arrien Pharmaceuticals, LLC, Arthrogen BV, Asahi Kasei Pharma Corp., Aslan Pharmaceuticals Pte. Ltd., Astellas Pharma Inc., AstraZeneca Plc, Avesthagen Limited, Avexxin AS, Axxam SpA, Bio-Cancer Treatment International Limited, BIOCAD, Biocon Limited, Biokine Therapeutics Ltd., BioLingus AG, Bionovis SA, BioTherapeutics Inc., Bird Rock Bio, Inc., Boehringer Ingelheim GmbH, Bone Medical Limited, Boryung Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd., Cardax Pharmaceuticals, Inc., CASI Pharmaceuticals Inc., CEL-SCI Corporation, Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., Cellworks Group, Inc., ChemoCentryx, Inc., Chipscreen Biosciences Ltd, ChironWells GmbH, Chong Kun Dang Pharmaceutical Corp., CJ HealthCare Corp., CLL Pharma, Coherus BioSciences, Inc., Commence Bio, Inc., Compugen Ltd., Confluence Life Sciences, Inc., CrystalGenomics, Inc., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Dong-A Socio Group, Dr. Reddy's Laboratories Limited, Effimune SAS, Eisai Co., Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Enceladus Pharmaceuticals BV, Endocyte, Inc., Ensemble Therapeutics Corporation, Ensol Biosciences Inc., Enzene Biosciences Ltd., Epirus Biopharmaceuticals, Inc., Exicure, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Fountain Biopharma Inc., Galapagos NV, Genentech, Inc., Genor BioPharma Co., Ltd., Genosco, Gilead Sciences, Inc., GlaxoSmithKline Plc, Griffin Discoveries BV, Handok Inc., Hanmi Pharmaceuticals, Co. Ltd., Hansa Medical AB, Hanwha Chemical Corporation, HEC Pharm Co., Ltd., Hetero Drugs Limited, Hospira, Inc., Huabo Biopharm Co., Ltd., Hutchison MediPharma Limited, Idera Pharmaceuticals, Inc., IMMD Inc., Immune Response BioPharma, Inc., ImmunoFrontier, Inc., Inbiopro Solutions Pvt. Ltd., Innate Pharma SA, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Invion Limited, ISU ABXIS Co.,Ltd., Jiangsu Hengrui Medicine Co., Ltd., Johnson & Johnson, Jyant Technologies, Inc., Kadmon Corporation, LLC, KAHR medical Ltd., Karus Therapeutics Limited, Kezar Life Sciences, Inc., Kineta, Inc., Lead Pharma Holding B.V., LG Life Science LTD., Lipocure Ltd., Lupin Limited, Mabion SA, Mabtech Limited, mAbxience S.A., MacroGenics, Inc., Mebiopharm Co., Ltd., MedAnnex Ltd, MediGene AG, MedImmune, LLC, Merck & Co., Inc., Mertiva AB, Mesoblast Limited, MetrioPharm AG, Mitsubishi Tanabe Pharma Corporation, Modern Biosciences Plc, ModiQuest B.V., Momenta Pharmaceuticals, Inc., Morphotek, Inc., Mycenax Biotech Inc., Myos Corporation, Myungmoon pharmaceutical Co.,Ltd., NanoSmart Pharmaceuticals, Inc., Navigen Pharmaceuticals, Inc., Neovacs SA, Nichi-Iko Pharmaceutical Co., Ltd., Nimbus Therapeutics, LLC, Novartis AG, NovImmune SA, Nuevolution A/S, Nuvo Research Inc., Omeros Corporation, Oncobiologics, Inc., OncoImmune, Inc., OPKO Health, Inc., Opsona Therapeutics Limited, Orchid Chemicals & Pharmaceuticals Ltd, Oscotec Inc., Padlock Therapeutics, Inc., Panacea Biotec Limited, Paras Biopharmaceuticals Finland Oy, Peptinnovate Limited, Peptinov SAS, Pfenex Inc., Pfizer Inc., Pharmacyclics, Inc., PharmaIN Corporation, Pharmedartis GmbH, Phenex Pharmaceuticals AG, Philogen S.p.A., Principia Biopharma Inc., Progenra, Inc., ProNoxis AB, ProtAb Ltd, Protagonist Therapeutics Inc., Protalex, Inc., Protalix BioTherapeutics, Inc., Provid Pharmaceuticals, Inc., Qu Biologics Inc., R-Pharm, Re-Pharm Limited, ReceptoPharm, Inc., RedHill Biopharma Ltd., Redx Pharma Plc, Regeneron Pharmaceuticals, Inc., Resverlogix Corp., ReveraGen BioPharma, Inc., Rhizen Pharmaceuticals S.A., Richter Gedeon Nyrt., Rottapharm SpA, Salix Pharmaceuticals Ltd., Sandoz International GmbH, Sareum Holdings Plc, SBI Biotech Co., Ltd., Selvita SA, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Shanghai Henlius Biotech Co., Ltd., Shanghai Pharmaceutical Co., Ltd., Swedish Orphan Biovitrum AB, Synovo GmbH, Syntrix Biosystems, Inc., TaiwanJ Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Limited, TechnoPhage SA, Teijin Pharma Limited, The International Biotechnology Center (IBC) Generium, TheraMAB LLC, Therapeutic Proteins International, LLC, TiGenix NV, Toleranzia AB, Tumorend, LLC, TxCell SA, U.S. Stem Cell, Inc., UCB S.A., ugichem GmbH, Unizyme Laboratories A/S, Vaccinex, Inc., Vichem Chemie Research Ltd., Vicore Pharma AB, Vida Therapeutics Inc., Vitae Pharmaceuticals, Inc., Vivia Biotech, S.L., Xbrane Bioscience AB, Xencor, Inc., XTL Biopharmaceuticals Ltd., Yuhan Corporation, Yungjin Pharm. Co., Ltd., Yuyu Pharma, Inc., Zenyaku Kogyo Co., Ltd., Zydus Cadila Healthcare Limited

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Gouty Arthritis (Gout) - Pipeline Review, H2 2015
-Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2015
-Systemic Lupus Erythematosus - Pipeline Review, H2 2015
-Myocardial Infarction - Pipeline Review, H2 2015
-Diabetic Nephropathy - Pipeline Review, H2 2015